Amgen says Repatha drug linked to fewer heart attacks in study
Amgen reported that its cholesterol medication Repatha was associated with a lower risk of heart attacks in patients compared to other treatments.
Study results show reduced risk
The company released data indicating that users taking Repatha experienced fewer instances of major cardiovascular events. This finding comes from an analysis comparing the drug against standard care options for high cholesterol. Researchers noted a distinct difference in heart attack rates between the two groups.
Data covers multiple patient groups
The analysis included thousands of individuals who received the therapy over several years of observation. Officials stated that the results support the continued use of the medication for eligible patients. Independent reviewers have since examined the statistical models used to reach these conclusions.
Regulatory bodies review new data
Health authorities are currently assessing whether the findings will change existing approval guidelines for the drug. The agency will look at safety profiles alongside the new efficacy information provided by Amgen. Decisions on labeling or usage restrictions depend on the final outcome of this review process.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.